You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cardiovascular conditions
  5. Embolism and thrombosis

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism

  • Technology appraisal guidance
  • Reference number: TA327
  • Published:  17 December 2014
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
Download guidance (PDF)
  • Overview
  • 1 Recommendations
  • 2 Information about dabigatran etexilate
  • 3 The company's submission
  • 4 Consideration of the evidence
  • 5 Implementation
  • 6 Appraisal committee members, guideline representatives and NICE project team
  • 7 Sources of evidence considered by the committee

1 Recommendations

1.1

Dabigatran etexilate is recommended, within its marketing authorisation, as an option for treating and for preventing recurrent deep vein thrombosis and pulmonary embolism in adults.


Next page 2 Information about dabigatran etexilate Previous page Overview